Acute Myeloid Leukemia as Second Tumor in a Patient with Burkitt’s Lymphoma: Literature Review and a Case Report

TT Valiev1, TYu Pavlova1, AM Kovrigina2, IN Serebryakova1

1 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

2 National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Timur Teimurazovich Valiev, MD, PhD, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; e-mail:

For citation: Valiev TT, Pavlova TYu, Kovrigina AM, Serebryakova IN. Acute Myeloid Leukemia as Second Tumor in a Patient with Burkitt’s Lymphoma: Literature Review and a Case Report. Clinical oncohematology. 2021;14(2):167–72. (In Russ).

DOI: 10.21320/2500-2139-2021-14-2-167-172


The application of highly effective tumor treatment protocols in children and increasing number of patients healed resulted in a growing focus on long-term effects of chemotherapy. One of the most dangerous complications of a first malignant neoplasm (MN) is the development of second MNs. Cytostatic drugs of the epipodophyllotoxin group and alkylating agents contribute to secondary acute myeloid leukemias (AML), the rare and prognostically very unfavorable second MNs. The present article provides a review of literature on risks of secondary hematological MNs associated with the therapy of first tumors. It also contains a case report of successful treatment of AML which occurred after Burkitt’s lymphoma therapy.

Keywords: second malignant neoplasms, acute myeloid leukemias, Burkitt’s lymphoma, children.

Received: December 10, 2020

Accepted: March 1, 2021

Read in PDF

Статистика Plumx английский


  1. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2007. Bethesda: National Cancer Institute; 2007.
  2. Meadows A, Friedman D, Neglia J, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62. doi: 10.1200/JCO.2008.21.1920.
  3. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083–95. doi: 10.1093/jnci/djq238.
  4. O’Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin’s lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28(7):1232–9. doi: 10.1200/JCO.2009.24.8062.
  5. Dorffel W, Riepenhausenl M, Luders H, et al. Secondary Malignancies Following Treatment for Hodgkin’s Lymphoma in Childhood and Adolescence. Dtsch Arztebl Int. 2015;112(18):320–7. doi: 10.3238/arztebl.2015.0320.
  6. Bhatia S, Yasui Y, Robison L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386–94. doi: 10.1200/JCO.2003.11.059.
  7. Pui C, Behm F, Raimondi S, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321(3):136–42. doi: 10.1056/NEJM198907203210302.
  8. Pui C. Therapy-related myeloid leukaemia. Lancet. 1990;336(8723):1130–1. doi: 10.1016/0140-6736(90)92607-j.
  9. Ratain M, Rowley J. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992;3(2):107–11. doi: 10.1093/oxfordjournals.annonc.a058121.
  10. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995;13(7):1557–63. doi: 10.1200/JCO.1995.13.7.1557.
  11. Hijiya N, Ness K, Ribeiro R, Hudson M. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115(1):23–35. doi: 10.1002/cncr.23988.
  12. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of hematopoietic and lymphoid tissues. Revised 4th edition. Lion: IARC Press; 2017. p. 581.
  13. Verdeguer A, Ruiz JG, Ferris J, et al. Acute non-lymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide. Med Pediatr Oncol. 1992;20(1):48–52. doi: 10.1002/mpo.2950200110.
  14. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatinum or cyclophosphamide for breast cancer. J Clin Oncol. 1992;10(9):1444–51. doi: 10.1200/JCO.1992.10.9.1444.
  15. Donatini B, Krupp P. Secondary pre-leukemia and etoposide. Lancet. 1991;338(8777):1269. doi: 10.1016/0140-6736(91)92133-M.
  16. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325(24):1682–7. doi: 10.1056/NEJM199112123252402.
  17. Ballen KK, Antin JH. Treatment of therapy related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin N Am. 1993;7(2):477–93. doi: 10.1016/s0889-8588(18)30253-3.
  18. Aguilera DG, Vaklavas C, Tsimberidou AM, et al. Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The MD Anderson Cancer Center Experience. J Pediatr Hematol Oncol. 2009;31(11):803–11. doi: 10.1097/MPH.0b013e3181ba43dc.
  19. De Witte T, Hermans J, van Biezen J, et al. Prognostic variables in bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey of the working party on leukemia. Bone Marrow Transplant. 1991;7(2):40.
  20. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007(1):453–9. doi: 10.1182/asheducation-2007.1.453.
  21. Xinan (Holly) Yang, Bin Wang, John M. Cunningham Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles. BMC Med Genom. 2015;8(2):S6. doi: 10.1186/1755-8794-8-S2-S6.
  22. Ковригина А.М. Пересмотренная классификация ВОЗ опухолей гемопоэтической и лимфоидной ткани, 2017 г. (4-е издание): миелоидные неоплазии. Архив патологии. 2018;80(6):43–9. doi: 10.17116/patol20188006143.
    [Kovrigina AM. A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms. Arkhiv patologii. 2018;80(6):43–9. doi: 10.17116/patol20188006143. (In Russ)]
  23. Itzykson R, Kosmider O, Fenaux P. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2013;26(4):355–64. doi: 10.1016/j.beha.2014.01.001.
  24. Семенова Н.Ю., Бессмельцев С.С., Ругаль В.И. Биология ниши гемопоэтических стволовых клеток. Клиническая онкогематология. 2014;7(4):501–11.
    [Semenova NYu, Bessmeltsev SS, Rugal VI. Biology of Hematopoietic Stem Cell Niche. Klinicheskaya onkogematologiya. 2014;7(4):501–11. (In Russ)]
  25. Rihani R, Bazzeh F, Faqih N, Sultan I. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer. 2010;116(18):4385–94. doi: 10.1002/cncr.25313.
  26. Nottage K, Lanktot J, Li Zh, et al. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. 2011;117(23):6315–8. doi: 10.1182/blood-2011-02-335158.
  27. Валиев Т.Т. Лимфома Беркитта у детей: 30 лет терапии. Педиатрия. Журнал им. Г.Н. Сперанского. 2020;99(4):35–41.
    [Valiev TT. Burkitt’s lymphoma in children: 30 years of therapy. Zhurnal im. G.N. Speranskogo. 2020;99(4):35–41. (In Russ)]
  28. Павлова Т.Ю., Валиев Т.Т. Вторые злокачественные опухоли у лиц, перенесших онкологическое заболевание в детстве. Педиатрия. Consilium Medicum. 2020;2:12–6. doi: 10.26442/26586630.2020.2.200234.
    [Pavlova TYu, Valiev TT. Second malignant tumors in pediatric cancer survivors. Consilium Medicum. 2020;2:12–6. doi: 10.26442/26586630.2020.2.200234. (In Russ)]
  29. Lee S-S. Therapy-related Acute Myeloid Leukemia Following Treatment for Burkitt’s Lymphoma. Chonnam Med J. 2017;53(3):229–30. doi: 10.4068/cmj.2017.53.3.229.
  30. Ripperger T, Bielack SS, Borkhardt B, et al. Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet Part A. 2017;173(4):1017–37. doi: 10.1002/ajmg.a.38142.